ArticleAnnals of hematology2026
Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite substantial therapeutic advances in multiple myeloma (MM), extramedullary disease (EMD) remains an aggressive subtype associated with poor prognosis, for which consensus on management is lacking and dedicated clinical trials are scarce. We conducted a retrospective single-center analysis of 86 patients with radiologically confirmed EMD, defined as soft-tissue involvement without bone contiguity (data cut-off September 30, 2024). The cohort included patients with de novo EMD (n = 19, 22%) and secondary EMD at relapse of MM (n = 67, 78%). We assessed clinical characteristics, survival outcomes, and treatment strategies. Treatment was highly heterogeneous, comprising > 50 distinct regimens. Median overall survival (mOS) from initial MM diagnosis was 55 months. mOS from EMD occurrence was 28 months for de novo and 21 months for secondary EMD. Survival varied by anatomical site: central nervous system (CNS), pulmonary, and retroperitoneal involvement showed a trend toward inferior survival, whereas lymph node involvement was associated with significantly longer survival in exploratory analyses (p = 0.011). Based on these findings, we exploratorily categorized anatomical sites into a three-tiered risk grouping, which revealed a stepwise gradient that did not reach statistical significance (p = 0.054). High-risk cytogenetic features were present in 50% of patients with de novo EMD and in 43% with secondary EMD. Novel agents, including CAR T-cell therapy and bispecific antibodies, were used predominantly in later lines, with responses in secondary EMD that were often transient. This real-world analysis confirms the high-risk nature of EMD, especially for patients with CNS, pulmonary, or retroperitoneal involvement. Given the observed treatment heterogeneity, prospective registries are urgently needed to define optimal therapeutic sequencing and address the high unmet therapeutic need in EMD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.